Frontline plc (FRO)
NYSE: FRO · Real-Time Price · USD
18.80
+0.38 (2.06%)
Aug 1, 2025, 4:00 PM - Market closed
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $23.33, which forecasts a 24.10% increase in the stock price over the next year. The lowest target is $20 and the highest is $30.
Price Target: $23.33 (+24.10%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 22, 2025.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $22 → $20 | Buy | Maintains | $22 → $20 | +6.38% | Apr 22, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $26 → $20 | Strong Buy | Maintains | $26 → $20 | +6.38% | Dec 17, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $26 | Strong Buy | Maintains | $26 | +38.30% | Nov 27, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $30 → $26 | Strong Buy | Maintains | $30 → $26 | +38.30% | Nov 14, 2024 |
| BTIG | BTIG | Hold → Strong Buy Upgrades $30 | Hold → Strong Buy | Upgrades | $30 | +59.57% | Oct 7, 2024 |
Financial Forecast
Revenue This Year
1.33B
from 2.05B
Decreased by -35.23%
Revenue Next Year
1.52B
from 1.33B
Increased by 14.38%
EPS This Year
2.25
from 2.23
Increased by 1.18%
EPS Next Year
3.02
from 2.25
Increased by 33.97%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.6B | 2.0B | 1.9B |
| Avg | 1.3B | 1.5B | 1.6B |
| Low | 1.2B | 1.1B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -21.2% | 49.8% | 25.3% |
| Avg | -35.2% | 14.4% | 7.4% |
| Low | -42.0% | -16.2% | -3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.31 | 4.69 | 5.03 |
| Avg | 2.25 | 3.02 | 3.80 |
| Low | 1.67 | 1.52 | 3.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 48.6% | 108.4% | 66.7% |
| Avg | 1.2% | 34.0% | 25.9% |
| Low | -25.2% | -32.6% | 6.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.